HEALTH

Amgen Wins Round in Patent Dispute: The Thousand Oaks-based biotechnology company said a federal judge in Massachusetts has upheld a judgment that precludes Genetics Institute Inc. from enforcing its patent for Epogen. Genetics Institute, which is controlled by American Home Products Corp., said it will appeal the decision. In March, 1991, the U.S. Court of Appeals said Cambridge, Mass.-based Genetic Institute’s patent for Epogen was invalid and unenforceable against Amgen. U.S. District Judge William G. Young upheld that decision. Epogen, one of the biggest-selling biotechnology products, is used to treat anemia in patients undergoing kidney dialysis.